View in EDS

Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs.

Saved in:
Bibliographic Details
Title: Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs.
Authors: Wei BR; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, United States., Peer CJ; Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States., Richardson WJ; Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States., Hewitt SM; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States., Figg WD; Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States., Simpson RM; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
Source: Frontiers in veterinary science [Front Vet Sci] 2022 Dec 14; Vol. 9, pp. 1056408. Date of Electronic Publication: 2022 Dec 14 (Print Publication: 2022).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101666658 Publication Model: eCollection Cited Medium: Print ISSN: 2297-1769 (Print) Linking ISSN: 22971769 NLM ISO Abbreviation: Front Vet Sci Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2297-1769
DOI:10.3389/fvets.2022.1056408